Induction treatment in patients with stage III non-small cell lung cancer

Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogeneous group of patients defined according to the extent and localization of disease. Patients with discrete N2 involvement identified preoperatively with resectable disease are candidates for multimodal therapy either with defin...

Descripción completa

Detalles Bibliográficos
Autores: Palmero, Ramón, Vilariño, Noelia, Navarro Martín, Arturo, Nadal, Ernest
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/176022
Acceso en línea:https://hdl.handle.net/2445/176022
Access Level:acceso abierto
Palabra clave:Càncer de pulmó
Quimioteràpia
Lung cancer
Chemotherapy
id ES_457e7a0158012cf57463edfe8d708e4e
oai_identifier_str oai:recercat.cat:2445/176022
network_acronym_str ES
network_name_str España
repository_id_str
spelling Induction treatment in patients with stage III non-small cell lung cancerPalmero, RamónVilariño, NoeliaNavarro Martín, ArturoNadal, ErnestCàncer de pulmóQuimioteràpiaLung cancerChemotherapyStage III non-small cell lung cancer (NSCLC) comprises a highly heterogeneous group of patients defined according to the extent and localization of disease. Patients with discrete N2 involvement identified preoperatively with resectable disease are candidates for multimodal therapy either with definitive chemoradiation therapy, induction chemotherapy, or chemoradiotherapy (CTRT) followed by surgery. Neoadjuvant chemotherapy has yielded comparable survival benefit to adjuvant chemotherapy in patients with stage II-III disease and may allow for downstaging the tumor or the lymph nodes, an earlier delivery of systemic treatment, and better compliance to systemic therapy. The use of immune checkpoint inhibitors (ICIs) as induction therapy shows encouraging activity and a favorable safety profile in patients with resectable early stage or locally advanced NSCLC. An unprecedented rate of pathological response and downstaging has been reported in single-arm clinical trials, especially when immunotherapy is combined with neoadjuvant chemotherapy. Ongoing randomized phase II/III clinical trials assessing the efficacy and safety of induction with immunotherapy plus chemotherapy have the potential to establish this therapeutic approach as a novel standard of care. These trials aim to validate pathological response as a surrogate marker of survival benefit and to demonstrate that this therapeutic strategy can improve the cure rate in patients with stage II-III NSCLC.AME Publishing Company2021202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion16 p.application/pdfhttps://hdl.handle.net/2445/176022Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.21037/tlcr-20-420Translational Lung Cancer Research, 2021, vol. 10, num. 1, p. 539-554https://doi.org/10.21037/tlcr-20-420cc by-nc-nd (c) Translational Lung Cancer Research, 2021http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1760222026-05-29T05:05:01Z
dc.title.none.fl_str_mv Induction treatment in patients with stage III non-small cell lung cancer
title Induction treatment in patients with stage III non-small cell lung cancer
spellingShingle Induction treatment in patients with stage III non-small cell lung cancer
Palmero, Ramón
Càncer de pulmó
Quimioteràpia
Lung cancer
Chemotherapy
title_short Induction treatment in patients with stage III non-small cell lung cancer
title_full Induction treatment in patients with stage III non-small cell lung cancer
title_fullStr Induction treatment in patients with stage III non-small cell lung cancer
title_full_unstemmed Induction treatment in patients with stage III non-small cell lung cancer
title_sort Induction treatment in patients with stage III non-small cell lung cancer
dc.creator.none.fl_str_mv Palmero, Ramón
Vilariño, Noelia
Navarro Martín, Arturo
Nadal, Ernest
author Palmero, Ramón
author_facet Palmero, Ramón
Vilariño, Noelia
Navarro Martín, Arturo
Nadal, Ernest
author_role author
author2 Vilariño, Noelia
Navarro Martín, Arturo
Nadal, Ernest
author2_role author
author
author
dc.subject.none.fl_str_mv Càncer de pulmó
Quimioteràpia
Lung cancer
Chemotherapy
topic Càncer de pulmó
Quimioteràpia
Lung cancer
Chemotherapy
description Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogeneous group of patients defined according to the extent and localization of disease. Patients with discrete N2 involvement identified preoperatively with resectable disease are candidates for multimodal therapy either with definitive chemoradiation therapy, induction chemotherapy, or chemoradiotherapy (CTRT) followed by surgery. Neoadjuvant chemotherapy has yielded comparable survival benefit to adjuvant chemotherapy in patients with stage II-III disease and may allow for downstaging the tumor or the lymph nodes, an earlier delivery of systemic treatment, and better compliance to systemic therapy. The use of immune checkpoint inhibitors (ICIs) as induction therapy shows encouraging activity and a favorable safety profile in patients with resectable early stage or locally advanced NSCLC. An unprecedented rate of pathological response and downstaging has been reported in single-arm clinical trials, especially when immunotherapy is combined with neoadjuvant chemotherapy. Ongoing randomized phase II/III clinical trials assessing the efficacy and safety of induction with immunotherapy plus chemotherapy have the potential to establish this therapeutic approach as a novel standard of care. These trials aim to validate pathological response as a surrogate marker of survival benefit and to demonstrate that this therapeutic strategy can improve the cure rate in patients with stage II-III NSCLC.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/176022
url https://hdl.handle.net/2445/176022
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.21037/tlcr-20-420
Translational Lung Cancer Research, 2021, vol. 10, num. 1, p. 539-554
https://doi.org/10.21037/tlcr-20-420
dc.rights.none.fl_str_mv cc by-nc-nd (c) Translational Lung Cancer Research, 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Translational Lung Cancer Research, 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 16 p.
application/pdf
dc.publisher.none.fl_str_mv AME Publishing Company
publisher.none.fl_str_mv AME Publishing Company
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407165336256512
score 15.812429

Similares en LA Referencia